March 4, 2019
BioPharmX enrolls patients to test new drug for skin condition rosacea
BioPharmX Corporation has enrolled patients for its Phase 2b testing BPX-04, a new drug limited by U.S. law to investigational use, topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea.